Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Cardiovascular Medicine
Published in: Current Treatment Options in Cardiovascular Medicine 2/2012

01-04-2012 | Vascular Disease (H Gornik and E Kim, Section Editors)

Update on the Biology and Treatment of Lymphedema

Author: Stanley G. Rockson, MD

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 2/2012

Login to get access

Opinion statement

The past decade has produced an explosion of insights into lymphatic vascular development and structural biology and, in parallel, into the function of the lymphatics in health and in disease. In lymphedema, there is a spectrum that extends from primary (heritable) to acquired causes of disease. The diagnosis of lymphatic edema implicates a very specific treatment approach that is predicated upon the favorable impact of physiotherapy upon lymph flow and protein clearance from the edematous zones of the body. The recognition of the unique biology that accompanies lymphatic causes of edema has stimulated new research directions that are likely to translate into exciting new pharmacologic and molecular approaches to diagnosis and treatment.
Literature
1.
2.
Rockson SG. How can lymphatic research influence lymphatic education? Lymphat Res Biol. 2004;2(2):67–8.PubMedCrossRef
3.
Rockson SG, Granger DN, Skeff KM, Chaite W. Lymphatic biology and disease: is it being taught? Who is listening? Lymphat Res Biol. 2004;2(2):86–95.PubMedCrossRef
4.••
Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol. 2008;52(10):799–806.PubMedCrossRef
5.•
Norrmen C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011;123(12):1335–51.PubMedCrossRef
6.
7.
8.
Hodge LM, Downey HF. Lymphatic pump treatment enhances the lymphatic and immune systems. Exp Biol Med (Maywood). 2011;236(10):1109–15.CrossRef
9.•
Detry B, Bruyere F, Erpicum C, Paupert J, Lamaye F, Maillard C, Lenoir B, Foidart JM, Thiry M, Noel A. Digging deeper into lymphatic vessel formation in vitro and in vivo. BMC Cell Biol. 2011;12:29.PubMedCrossRef
10.
Nakamura K, Rockson SG. Molecular targets for therapeutic lymphangiogenesis in lymphatic dysfunction and disease. Lymphat Res Biol. 2008;6(3–4):181–9.PubMedCrossRef
11.
An A, Rockson SG. The potential for molecular treatment strategies in lymphatic disease. Lymphat Res Biol. 2004;2(4):173–81.PubMedCrossRef
12.
Ferrell RE, Kimak MA, Lawrence EC, Finegold DN. Candidate gene analysis in primary lymphedema. Lymphat Res Biol. 2008;6(2):69–76.PubMedCrossRef
13.
Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, Karlsson JM, Baty CJ, Ferrell RE. HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol. 2008;6(2):65–8.PubMedCrossRef
14.
Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg. 1999;177(3):184–7. discussion 188.PubMedCrossRef
15.
16.
Szuba A, Shin WS, Strauss HW, Rockson S. The third circulation: radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med. 2003;44(1):43–57.PubMed
17.
Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002;(in press).
18.
Tabibiazar R, Cheung L, Han J, Swanson J, Beilhack A, An A, Dadras SS, Rockson N, Joshi S, Wagner R, Rockson SG. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 2006;3(7):e254.PubMedCrossRef
19.
Avraham T, Daluvoy S, Zampell J, Yan A, Haviv YS, Rockson SG, Mehrara BJ. Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair. Am J Pathol. 2010;177(6):3202–14.PubMedCrossRef
20.•
Zampell JC, Yan A, Avraham T, Andrade V, Malliaris S, Aschen S, Rockson SG, Mehrara BJ. Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response to lymphedema. Am J Physiol Cell Physiol. May;300(5):C1107–1121. This is an animal study that underscores the importance of tissue injury responses as an integral component of the biology of lymphedema.
21.
Beilhack A, Rockson SG. Immune traffic: a functional overview. Lymphat Res Biol. 2003;1(3):219–34.PubMedCrossRef
22.
Johnson LA, Jackson DG. Cell traffic and the lymphatic endothelium. Ann N Y Acad Sci. 2008;1131:119–33.PubMedCrossRef
23.
Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002;21(7):1505–13.PubMedCrossRef
24.
Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98(6):769–78.PubMedCrossRef
25.
Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, Sleeman MW, Oliver G. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet. 2005;37(10):1072–81.PubMedCrossRef
26.
Brorson H, Ohlin K, Olsson G, Karlsson M. Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol. 2009;7(1).
27.
Brorson H, Ohlin K, Olsson G, Langstrom G, Wiklund I, Svensson H. Quality of life following liposuction and conservative treatment of arm lymphedema. Lymphology. 2006;39(1):8–25.PubMed
28.
Brorson H. Liposuction in arm lymphedema treatment. Scand J Surg. 2003;92(4):287–95.PubMed
29.
Brorson H, Svensson H. Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone. Plast Reconstr Surg. 1998;102(4):1058–67. discussion 1068.PubMedCrossRef
30.
Cheung L, Han J, Beilhack A, Joshi S, Wilburn P, Dua A, An A, Rockson SG. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs. 2006;20(6):363–70.PubMedCrossRef
31.
Schneider M, Ny A, Ruiz de Almodovar C, Carmeliet P. A new mouse model to study acquired lymphedema. PLoS Med. 2006;3(7):e264.PubMedCrossRef
32.
Jin D, An A, Liu J, Nakamura K, Rockson S. Therapeutic Responses to Exogenous VEGF-C Administration in Experimental Lymphedema: Immunohistochemical and Molecular Characterization Lymphat Res Biol. 2009;7(1).
33.
Lahteenvuo M, Honkonen K, Tervala T, Tammela T, Suominen E, Lahteenvuo J, Kholova I, Alitalo K, Yla-Herttuala S, Saaristo A. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation. 2011;123(6):613–20.PubMedCrossRef
34.
Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer. 2006;95(12):1611–25.PubMedCrossRef
35.
Cornish B. Bioimpedance analysis: scientific background. Lymphat Res Biol Spring. 2006;4(1):47–50.CrossRef
36.
Ward LC. Bioelectrical impedance analysis: proven utility in lymphedema risk assessment and therapeutic monitoring. Breast Cancer Res Treat. 2006;4(1):51–6.
37.
Szuba A, Cooke JP, Yousuf S, Rockson SG. Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. Am J Med. 2000;109(4):296–300.PubMedCrossRef
38.
Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, Bryan CJ, Williams-Smith CT, Greene QP. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009;361(7):664–73.PubMedCrossRef
39.
Szuba A, Razavi M, Rockson SG. Diagnosis and treatment of concomitant venous obstruction in patients with secondary lymphedema. J Vasc Interv Radiol. 2002;13(8):799–803.PubMedCrossRef
40.
Raju S, Furrh JBt, Neglen P. Diagnosis and treatment of venous lymphedema. 2011; J Vasc Surg. Sep 27 [Epub ahead of print].
41.
Damstra RJ, Voesten HG, van Schelven WD, van der Lei B. Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of 11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Res Treat. 2009;113(2):199–206.PubMedCrossRef
42.
Weiss M, Baumeister RG, Hahn K. Dynamic lymph flow imaging in patients with oedema of the lower limb for evaluation of the functional outcome after autologous lymph vessel transplantation: an 8-year follow-up study. Eur J Nucl Med Mol Imaging. 2003;30(2):202–6.PubMedCrossRef
43.
Campisi C, Boccardo F. Microsurgical techniques for lymphedema treatment: derivative lymphatic-venous microsurgery. World J Surg. 2004;28(6):609–13.PubMedCrossRef
44.
Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg. 2006;243(3):313–5.PubMedCrossRef
45.
Brorson H, Svensson H. Complete reduction of lymphoedema of the arm by liposuction after breast cancer. Scand J Plast Reconstr Surg Hand Surg. 1997;31(2):137–43.PubMedCrossRef
46.
McGeown JG, McHale NG, Thornbury KD. Effects of varying patterns of external compression on lymph flow in the hindlimb of the anaesthetized sheep. J Physiol. 1988;397:449–57.PubMed
47.
Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer. 2002;95(11):2260–7.PubMedCrossRef
48.
Wilburn O, Wilburn P, Rockson SG. A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412]. BMC Cancer. 2006;6:84.PubMedCrossRef
49.
Rockson SG. Current concepts and future directions in the diagnosis and management of lymphatic vascular disease. Vasc Med. 2010;15(3):223–31.PubMedCrossRef
50.
Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A. 2001;98(22):12677–82.PubMedCrossRef
51.
Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000;25(2):153–9.PubMedCrossRef
52.
Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome [in process citation]. Am J Hum Genet. 2000;67(6):1382–8.PubMedCrossRef
53.
Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, Vikkula M. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet. 2003;72(6):1470–8.PubMedCrossRef
Metadata
Title
Update on the Biology and Treatment of Lymphedema
Author
Stanley G. Rockson, MD
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Treatment Options in Cardiovascular Medicine / Issue 2/2012
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-012-0170-0

Other articles of this Issue 2/2012

Current Treatment Options in Cardiovascular Medicine 2/2012 Go to the issue

Vascular Disease (H Gornik and E Kim, Section Editors)

Chronic Cerebrospinal Venous Insufficiency as a Cause of Multiple Sclerosis: Controversy and Reality

Vascular Disease (H Gornik and E Kim, Section Editors)

Endovascular Therapy for Vasculogenic Erectile Dysfunction

Vascular Disease (H Gornik and E Kim, Section Editors)

Approach to Lipid Therapy in the Patient With Atherosclerotic Vascular Disease

Vascular Disease (H Gornik and E Kim, Section Editors)

Renal Sympathetic Denervation for Treatment of Hypertension

Vascular Disease (H Gornik and E Kim, Section Editors)

Management of Infrapopliteal Peripheral Arterial Occlusive Disease

Vascular Disease (H Gornik and E Kim, Section Editors)

Endovascular Therapy for Thoracic Aortic Aneurysms: State of the Art in 2012